A satellite symposium in conjunction with Oncology Pharmacists Connect 2023.
If you would like to attend in person, please visit our Oncology Pharmacists Connect 2023 registration page: www.pharmacytimes.org/Connect2023
Program Description
Though the prognosis in patients with non-small cell lung cancer (NSCLC) has improved primarily due to advancements in screening, techniques in diagnosis and treatment, and novel agents such as targeted therapies and immunotherapies, patients with NSCLC with exon 20 mutations continue to have lower overall survival. Until recently, treatment options targeting this mutation were limited, but 2 epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors that target the most common mutations of EGFR, including the exon 20 insertion mutation, have been recently approved. Oncology pharmacists are optimally poised to improve care coordination and support both patients and the oncology care team in many ways. This program will explore the major role pharmacists can play in educating other health care providers on drug interactions, adverse effects, efficacy of therapy, and dosage adjustments to improve treatment adherence and survival outcomes for patients receiving EGFR exon 20-targeted therapies for NSCLC.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: June 16, 2023
Expiration date: August 16, 2023
Time to complete activity: 1.0 hour
Learner level: Intermediate, Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore guideline-directed testing methods for detecting epidermal growth factor receptor (EGFR) exon 20 insertion mutations
- Analyze the clinical evidence for EGFR exon 20-targeted therapies and potential benefits and risks associated with their use
- Employ strategies for the prevention and management of toxicities associated with therapies targeting EGFR exon 20 insertion mutations
